Media headlines about Merus Labs International (NASDAQ:MSLI) (TSE:MSL) have trended positive this week, according to AlphaOne Sentiment. AlphaOne, a division of Accern, scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Merus Labs International earned a media sentiment score of 0.35 on AlphaOne’s scale. AlphaOne also assigned media stories about the company an impact score of 25 out of 100, meaning that recent press coverage is very unlikely to have an impact on the stock’s share price in the near future.
Shares of Merus Labs International (NASDAQ:MSLI) traded up 6.31% on Friday, reaching $1.18. The company’s stock had a trading volume of 1,479,359 shares. The stock’s market cap is $138.47 million. Merus Labs International has a 12-month low of $0.70 and a 12-month high of $1.45. The firm has a 50 day moving average price of $0.88 and a 200-day moving average price of $0.87.
Merus Labs International (NASDAQ:MSLI) last posted its quarterly earnings results on Tuesday, February 14th. The company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by $0.02. The firm had revenue of $19.53 million for the quarter, compared to analysts’ expectations of $23.18 million. Merus Labs International had a negative net margin of 10.36% and a negative return on equity of 3.94%. Equities research analysts expect that Merus Labs International will post ($0.02) EPS for the current year.
Several equities research analysts recently commented on the company. Bloom Burton reaffirmed a “hold” rating on shares of Merus Labs International in a research report on Monday, February 13th. Zacks Investment Research raised Merus Labs International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 15th. Finally, Canaccord Genuity set a $3.00 price objective on Merus Labs International and gave the company a “buy” rating in a research report on Sunday, February 12th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $3.88.
ILLEGAL ACTIVITY NOTICE: “Merus Labs International (MSLI) Earning Positive Press Coverage, Report Shows” was posted by Mideast Time and is owned by of Mideast Time. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.mideasttime.com/merus-labs-international-msli-earning-positive-press-coverage-report-shows/1708321.html.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.